New generation of SOPHiA
DDMTM integrates
latest advancements in data processing and technology
to deliver elevated experience and capabilities to
customers
BOSTON and ROLLE, Switzerland, Sept. 4,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a global leader in
data-driven medicine, today launched the new generation of the
SOPHiA DDMTM Platform. The new-gen SOPHiA
DDMTM Platform offers a new architecture designed
to more efficiently compute large amounts of data at-scale, while
elevating customer experience with integrated access to multimodal
analytics modules.
As cancer cases continue to rise across the globe, our
understanding of the disease becomes more nuanced. Newer, more
effective therapies are being developed each day, and data is
becoming increasingly critical in diagnosis, therapy selection, and
drug development. Since launching the first generation of
SOPHiA DDM TM in 2015, the Platform has
been at the forefront of these innovations, accelerating the
practice of data driven medicine globally as a leading platform in
healthcare for using data to improve patient care. Data computed
daily by the Platform has surged over the years with over 1.8
million genomic profiles being analyzed on the platform, at a rate
of almost 30,000 analyses per month.
As the volume and utility of data grows, SOPHiA GENETICS
continues to accelerate innovation in the field of data-driven
medicine by unveiling best-in-class technology and data science
capabilities. The new generation SOPHiA
DDM TM Platform offers a new, web-based
architecture, which allows the Platform to compute and process data
more efficiently by leveraging microservices as well as the newest
technologies in cloud computing and GPUs from partners such as
NVIDIA and Microsoft.
Faster data processing not only optimizes computing, but it also
provides answers more rapidly. Customers will experience faster
turnaround time from data upload to insights. In addition, more
efficient data processing capabilities enable the launch of new
capabilities, such as the new whole genome sequencing (WGS)
application being released later this year. It also enables new
capabilities in multimodal analytics, which require processing of
more complex and sizeable data sets across data modalities.
Under the new generation of SOPHiA DDMTM, genomic,
radiomic, and multimodal analytics capabilities will be offered in
a single, integrated workspace. Customers benefit from the three
analytics modules by selecting applications that best suit their
needs:
- Genomics: Ingests genomics FASTQ and VCF data to efficiently
call, annotate, and pre-classify oncogenic or pathogenic
variants.
- Radiomics: Processes data from various imaging modalities
(e.g., CT scans, PET-CT, MRI), segments anatomical areas of
interest, and extracts radiomic features for further analysis.
- Multimodal: Aggregates data from the radiomics and genomics
modules, along with processed clinical, biological, and
histological data, to train and verify predictive models at the
individual patient level.
"As our understanding of diseases becomes even more nuanced, we
need to continue to grow and adapt our solutions to be able to
field this complexity with speed and accuracy. Our customers are
relying on us to provide them with innovative solutions that can
accelerate their workflows," said Zhenyu
Xu, Chief Scientific Officer, SOPHiA
GENETICS. "Our decentralized, multimodal
analytics platform supports customers and helps break data silos by
creating a global community where knowledge is safely and securely
shared amongst users. The new generation of our SOPHiA
DDMTM Platform is revolutionizing the user experience by
blending our powerful AI algorithms with multimodal data to produce
meaningful insights to further the field of precision
medicine."
Abhimanyu Verma, Chief Technology
Officer, SOPHiA GENETICS, added, "We
pride ourselves on adapting our technology to meet our customers'
needs. As the technology infrastructure at most healthcare
organizations worldwide has evolved, we are thrilled to continue to
provide best-in-class technology and set them up for success. This
new generation of our platform will allow us the flexibility to
respond quickly to our customer's evolving needs and introduce new
features faster, and more efficiently."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM and connect
on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq:
SOPH) is a cloud-native healthcare technology company on a mission
to expand access to data-driven medicine by using AI to unlock
insights to deliver world-class care to patients across the globe.
It is the creator of SOPHiA DDM™, a platform that analyzes complex
genomic and multimodal data and generates real-time, actionable
insights for a broad global network of hospital, laboratory, and
biopharma institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements
are subject to risks and uncertainties, and actual results may
differ materially from those expressed or implied in the
forward-looking statements due to various factors, including those
described in our filings with the U.S. Securities and Exchange
Commission. No assurance can be given that such future results will
be achieved. Such forward-looking statements contained in this
press release speak only as of the date hereof. We expressly
disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-unveils-new-generation-of-the-sophia-ddmtm-platform-at-morgan-stanley-healthcare-conference-2024-302237655.html
SOURCE SOPHiA GENETICS